Mesoblast (ASX:MSB) Ending Cash Position: A$195.61 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ASX:MSB Mesoblast Ltd ASX:MSB
40 GF Score
Price A$2.77
! 4 Warning Signs
View Full Analysis

What is Mesoblast Ending Cash Position?

Mesoblast ASX:MSB +6.95% 40 Ending Cash Position is A$195.61 Mil as of Dec. 2025. GuruFocus rates ASX:MSB with a GF Score™ of 40/100. The stock has 4 warning signs investors should review.

Mesoblast's Ending Cash Position for the quarter that ended in Dec. 2025 was A$195.61 Mil.

Mesoblast's quarterly Ending Cash Position declined from Jun. 2025 (A$248.14 Mil) to Sep. 2025 (A$219.39 Mil) and declined from Sep. 2025 (A$219.39 Mil) to Dec. 2025 (A$195.61 Mil).

Mesoblast's annual Ending Cash Position declined from Jun. 2023 (A$106.26 Mil) to Jun. 2024 (A$94.82 Mil) but then increased from Jun. 2024 (A$94.82 Mil) to Jun. 2025 (A$248.14 Mil).

Mesoblast Ending Cash Position Related Terms

Mesoblast Ending Cash Position Historical Data

* Premium members only.

The historical data trend for Mesoblast's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Mesoblast Ending Cash Position Chart

Mesoblast Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Ending Cash Position
Get a 7-Day Free Trial Premium Member Only Premium Member Only 179.04 86.02 106.26 94.82 248.14

Mesoblast Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Ending Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 288.93 248.14 219.39 195.61 173.64
ASX:MSB
40GF Score
Mesoblast Ltd ASX:MSB
Ending Cash Position is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Mesoblast Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

Mesoblast's Ending Cash Position for the fiscal year that ended in Jun. 2025 is calculated as

Ending Cash Position= Beginning Cash Position+Net Change in Cash
=96.706+151.436
=248.14

Mesoblast's Ending Cash Position for the quarter that ended in Dec. 2025 is calculated as

Ending Cash Position=Beginning Cash Position+Net Change in Cash
=217.802+-22.19
=195.61

Frequently Asked Questions Learn more about Ending Cash Position →
What does a Ending Cash Position of A$195.61 Mil mean?
Mesoblast (ASX:MSB) has a Ending Cash Position of A$195.61 Mil as of Dec. 2025. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on Mesoblast and its competitors.
Is Mesoblast's Ending Cash Position too high?
Mesoblast's current Ending Cash Position is A$195.61 Mil. Overall, Mesoblast has a GF Score™ of 40/100, reflecting its overall financial health beyond just this single metric.
How does Mesoblast's Ending Cash Position compare to VRTX and REGN?
Mesoblast's Ending Cash Position of A$195.61 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Ending Cash Position for a Biotechnology company?
A good Ending Cash Position depends on the Biotechnology industry context. However, Ending Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Ending Cash Position mean?
A high Ending Cash Position can signal that a stock is expensive relative to its fundamentals. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on Mesoblast and its competitors. Mesoblast's current Ending Cash Position is A$195.61 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Mesoblast stock overvalued right now?
Mesoblast (ASX:MSB) has a current Ending Cash Position of A$195.61 Mil. The current Ending Cash Position is A$195.61 Mil. Mesoblast's overall GF Score™ is 40/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Ending Cash Position calculated?
Ending Cash Position is calculated from a company's financial statements. For Mesoblast (ASX:MSB), the current Ending Cash Position is A$195.61 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Mesoblast Business Description

Address 55 Collins Street, Level 38, Melbourne, VIC, AUS, 3000
Mesoblast Ltd is a commercial-stage biotechnology company and a world leader in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions. The company's product candidates include: Ryoncil (remestemcel-L) for the treatment of steroid-refractory acute graft versus host disease, as well as for the treatment of moderate to severe acute respiratory distress syndrome; Revascor (rexlemestrocel-L) for the treatment of chronic heart failure; and Rexlemestrocel-L for chronic low back pain. The company is managed as one operating segment, being the development of an adult stem cell technology platform for commercialization.
40GF Score

Get the complete analysis for ASX:MSB

Ending Cash Position is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$2.77
Price